Topic Listing for ArQule

Abandonment Able Renew Such Insurance Expires
Acceptance Application Agreement Applicable Law Access Legal Counsel
Account Agreement Account Ownership
Accounting Changes Error Corrections Accounting Costs Associated Exit Disposal Activities
Accounting Experience Accounting Impairment Disposal Long-lived Assets
Accounting Income Taxes Accounting Leases
Accounting Revenue Arrangements Multiple Deliverables Accounting Stock Issued Employees
Accounting Stock-based Compensation Accounts Payable Accrued Expenses
Acquire New Technologies Necessary Acquisition Related Charges
Acting Chief Financial Officer Activated Checkpoint Therapy
Addendum Charter Audit Committee Board Directors Arqule Inc Addendum Credit Line Account Application Agreement
Additional Clinical Activities Additional Pre-clinical Program
Administration Eligibility Administration Plan
Agreement Milestone Payments Royalties Agreements Employees Consultants Collaborators Not Afford Adequate Protection
Akip Discovery Platform Alliance Managers
Amended Restated 1996 Director Stock Option Plan Amendment
Amendment Employment Agreement Amendment Termination
Amendments Discontinuation Plan Amendments Registrants Code Ethics Waiver Provision
Annual Meeting Stockholders Held 2006 Anti-metastatic Findings
Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition Anti-tumor Activity
Apply Net Proceeds Sale Shares Manner Set Forth Arq 197
Arq 197 Agreement Arq 197 C-met
Arq 197 C-met Program Arq 501 171
Arq 501 761 171 E2f-1 Program Arq 501 761 E2f-1 Activators
Arq 621 Eg5 Inhibitor Arq 621 Eg5 Program
Arq-350rp-b-raf Kinase Inhibitors Arq-450rp-mitotic Checkpoint Activator
Arq-550rp-e2f Modulation Arqule
Arqule 2006 Approximately 109000000 Cash Marketable Securities Arqule Announces Management Board Changes
Arqule Announces Offering Common Stock Arqule Inc
Arqule Inc Amended Restated 1996 Director Stock Option Arqule Inc Registrant Entered Employment Agreement Nigel
Arqule Kinase Inhibitor Platform Akip Arqule License Grants
Arqule Prosecution Rights Arqules Fibroblast Growth Factor Program
Arqules Kinase Inhibitor Discovery Platform Assignment
Attendance Meetings Audit Committee
Audited Party Authorized Signatory Borrower Persons Designated Applicable Ubs Bank
Aviso Para Fiador Spanish Translation Required Law B-raf Kinase Inhibition
Base Salary Base Salary Target Amount Bonus
Basis Consolidation Basis Presentation
Bayer Because Not Intend Pay Dividends Stockholders Benefit Investment
Because Stock Price Extremely Volatile Experience Substantial Decline Benchmarking
Beneficial Ownership Reporting Compliance Benefit Resources Strengths Collaborators
Binding Agreement Legal Valid Obligation Such Party Enforceable Board Committees Meetings
Board Directors Amended Restated Plan 1998 Board Directors Amended Restated Plan 2000
Board Directors Amended Restated Plan 2001 Board Directors Amended Restated Plan 2002
Board Directors Amended Restated Plan 2003 Board Directors Amended Restated Plan 2004
Board Directors Amended Restated Plan 2005 Board Directors Amended Restated Plan 2006
Board Directors Amended Restated Plan 2007 Board Directors Amended Restated Plan 2009
Board Directors Authorized Amendment Restatement Plan 2005 Effective Board Directors Recommends Vote Election Nominees Listed Above
Board Directors Recommends Vote Proposal Board Directors Update
Board Recommends Vote Proposals Boston Biomedical Inc
Boston Biomedical Inc Collaboration Breach
Brian Schwartz Chief Medical Officer Broad Discretion Net Proceeds Offering Not Effectively
Build Pharmaceutical Biotechnology Expertise Management Scientific Teams Business Combinations
Business Development Business Overview
Business Relationships Business Strategy
C-met Cancer Survival Pathway Platform C-met Program
C-met Program-arq 197 C-metassociated Soft Tissue Sarcomas
Cancellation Election Participate Cancer Survival Pathways Platform
Cash Equivalents Marketable Securities Cash Flow Financing Activities
Cash Flow Investing Activities Cash Flow Operating Activities
Certain Covenants Hereby Agrees Certain Other Information
Certain Relationships Related Transactions Certificate Amendment Amended Restated Incorporation Arqule Inc
Certificate Chief Executive Officer Certificate Chief Executive Officer Financial
Certificate Chief Executive Officer Principal Financial Certificate Chief Financial Officer
Certificate Principal Executive Financial Officer Certificate Principal Financial Officer
Certificate Prinicpal Executive Financial Officer Changes Corrections Information Application Initialed
Changes Internal Control Changes Internal Control Over Financial Reporting
Charters Check Appropriate Box Below Form 8-k Filing Intended
Chemical Chemical Biological Materials Hazardous Violates Applicable Laws Causes
Chemical Hazardous Materials Violates Applicable Laws Causes Personal Chemistry Services Business
Chief Financial Officer Chief Medical Officer
Choose Acquire Complementary Businesses Products Technologies Instead Developing Clinical Development
Clinical Regulatory Plan Clinical Stage Products
Clinical Trial Clinical Trials
Cmc Clinical Collaboration Compounds Research Program Preclinical Studies Stage Other
Collaborations Alliances Collaborative Research Development License Agreement
Collaborators Restrict Scientific Information Collateral Account Ubs Financial Services Inc
Colorectal Cancer Committees Between Parties Matters Related Collaboration Without Limiting
Committees Board Committees Process
Common Stock Common Stock Par Value
Communication Audit Committees Communications Directors
Compared 2003 Compared 2004
Compared 2005 Compared 2006
Compared 2007 Comparison Cumulative Total Return Arqule Inc Nasdaq Stock
Compensation Committee Report Compensation Committees Process
Compensation Nominating Governance Committee Compensation Nominating Governance Committee Interlocks Insider Participation
Compensation Philosophy Competition
Compliance 409a Code Compliance Oversight Responsibilities
Comply Rule 433 Act Without Reliance 164 Compounds Related Backup Commercialization Licensed Products Without Limiting
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risk Conclusion
Conclusion Regarding Effectiveness Disclosure Controls Procedures Confidentiality
Consent Independent Registered Public Accounting Firm Consolidated Financial Statements
Contact Contacts
Continue Exploit Strength Chemistry Oncology Drug Discovery Development Continuing Incumbent Directors Terms Expiring 2010 Annual Meeting
Continuing Incumbent Directors Terms Expiring 2011 Annual Meeting Continuing Incumbent Directors Terms Expiring Annual Meeting Held
Control Controls Procedures
Cooperation Corporate Code Conduct
Corporate Development Corporate Governance
Corporate Governance Guidelines Corporate Governance Management
Corporate Partnerships Cost Compound Development Revenue
Cost Containment Pressures Affect Commercialization Revenues Generated Products Cost Revenue Compound Development Gross Margin Percentage
Counterparts Covenant Not Sue
Creation Direct Financial Obligation Off-balance Sheet Arrangement Credit Line Account
Credit Line Agreement Demand Facility Critical Accounting Policies Estimates
Current General Release Current Report
Cyclis Pharmaceuticals Inc Daiichi Sankyo
Daiichi Sankyo Akip Oncology Collaboration Daiichi Sankyo Ltd
Daiichi Sankyo Ltd Arq 197 Agreement Daiichi Sankyo Ltd Kinase Inhibitor Discovery Agreement
Date 2006 Date Achieved Measurable Progress Clinical Development Programs Said
Date Report Earliest Event Reported 2006 Arqule Inc Date Report Earliest Event Reported 2007 Arqule Inc
Dear Shareholders Debt
Deductibility Deduction Compensation
Deemed Termination Definitions
Delays Clinical Testing Result Increased Costs Delay Ability Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Description Arq 197
Designated Primary Development Compounds Backup Purposes Agreement Determination Option Price
Development Products Early Stage Based Scientific Platforms Unproven Development Products Early Stage Not Successfully Develop Drug
Development Strategy Director Compensation
Director Independence Director Qualifications
Director Qualifications Nomination Process Directors Executive Officers Corporate Governance
Disability Insurance Discovery
Dividend Policy Document Constitutes Part Prospectus Covering Securities Been Issued
Documents Incorporated Reference Drug Discovery
Drug Discovery Development Programs Not Progress Anticipated Revenue Drug Discovery Development Strategy
Drug Research Development Industry Highly Competitive Compete Some Drug Research Development Industry History Patent Other Intellectual
E2f-1 Program Earnings Loss Per Share
Edgewood Effective Date Agreement Termination Shall Become Parties Hereto
Effective Date Approvals Electronic Delivery Future Shareholder Communications
Electronic Delivery Future Stockholder Communications Elements Compensation
Eligible Employees Employee Non-disclosure Inventions Agreement
Employees Employees Rights Shareholders
Employment Agreement Employment Agreement Brian Schwartz
Employment Agreement Nigel Rulewski Employment Agreement Paolo Pucci
Employment Agreement Peter Lawrence Employment Agreement Stephen Hill
Employment Agreement Thomas Chan Employment Agreements
Employment Contracts Entire Agreement
Entire Agreement Amendment Entire Understanding
Entry Material Definitive Agreement Establishment Credit Line Termination
Estimates Even Collaborators Bring Products Market Unable Effectively Price
Even Drug Candidates Obtain Regulatory Approval Collaborators Subject Exclusion
Exclusive License Agreement Execution General Release
Executive Compensation Executive Employment Agreements
Executive Officers Executive Vice President General Counsel Chief Business Officer
Exercise Co-commercialization Option Exercise Rights Method Payment
Exhibits Exit Chemistry Services Business
Exit Chemistry Services Operations Experience Immediate Dilution Book Value Per Share Common
Exposed Potential Liability Related Development Testing Manufacturing Compounds Face Fierce Competition Competitors Greater Resources
Face Potential Liability Related Privacy Health Information Obtain Fair Value Financial Instruments
Federal Income Tax Consequences Relating Director Plan Options Federal Income Tax Consequences Relating Purchase Plan
Federal Income Tax Consequences Relating Stock Options Federal Income Tax Considerations
Filed Copy Certificate Been Forwarded New Castle County Filing Prosecution Maintenance Patent Rights
Financial Financial Information
Financial Statement Disclosure Matters Financial Statement Schedules
Financial Statements Exhibits Focus Cancer Market Large Unmet Need
Focus Small Molecule Drugs Foreign Currency
Form 10-k Form 10-q
Form 8-k Form Options
Forward Looking Statements Forward-looking Statements
Funds Associated Certain Auction Rate Securities Not Accessible Further Execution
Future Sales Common Stock Depress Price Gaap Application
Gaap Knowledge Gain Loss Sale Exchange Director Plan Shares
General General Administrative
General Administrative Costs Nine-month Periods 2008 3496000 13419000 General Information
General Release General Release Covenant Not Sue
Germ Cell Tumors Glaxosmithkline
Governing Law Governing Law Venue
Government Regulation Grant Options Option Terms
Group Health Dental Vision Coverage Grow Organically Through Business Development
Guiding Principles Hepatocellular Carcinoma
Hoffmann-la Roche Alliance Http Wwwarqulecom
Http Wwwsecgov Impairment Disposal Long-lived Assets
Implementation Development Program Important Disclosure Required Payments
Important Factors Regarding Forward-looking Statements Included License Agreements
Income Taxes Indemnification
Indemnification Limitation Liability Bank Securities Intermediary Independence Discussions Audit Committees
Index Consolidated Financial Statements Insurance Other Benefits
Intellectual Property Rights Interest
Interest Expense Interest Income
Interest Income Expense Other Interest Rate Swap Agreement
Interim Phase Results Arq 501 Internal Control Over Financial Reporting
Internal Control-integrated Framework Interpretation
Introduction Investment Income
Investment Income Interest Expense Investment Representations
Investments Non-marketable Equity Securities Investor Conference Call
Issuance Stock Johnson
Joint Credit Line Account Agreement Suspension Cancellation Joint Steering Committee
Key Compensation Elements Key Functions Responsibilities
Kinase Inhibitor Discovery Agreement Kyowa Hakko Kirin Ltd
Kyowa Hakko Kirin Ltd Licensing Agreement Kyowa Hakko Kogyo Ltd Alliance
Kyowa Licensing Agreement Laura Avakian
Leases Legal Proceedings
License Co-development Co-commercialization Agreement Licensed Product Commercialization
Licensed Technology Existing Effective Date Controlled Arqule Life Insurance Coverage
Limit Participation Limitation Audit Committees Role
Limitation Rights Limitations Grants
Limited Clinical Development Commercialization Experience List Schedules
Loss Investment Loss Per Share
Maintain Transfer Agent Necessary Jurisdiction Incorporation Registrar Common Managements Report Internal Control Over Financial Reporting
Manuscripts Deliverables Market Registrants Common Stock Related Stockholder Matters Issuer
Marketing General Administrative Materials Necessary Manufacture Product Candidates Currently Development Not
Meetings Membership
Michael Astrue Michael Loberg Phd
Mit Tumor Trial Name Borrower
Nancy Simonian Nature Operations Basis Presentation
Need Substantial Additional Funding Unable Raise Capital Needed Net Income Loss
Net Income Loss Per Share Net Investment Income
Net Loss Per Share New Plan Benefits
New Tax Rules Affecting Nonqualified Deferred Compensation Plans Nigel Rulewski Drcog Dch Chief Medical Officer
Nine-month Period Primarily Due Non-cash Stock-based Compensation Nominees Terms Expiring 2011 Annual Meeting
Nominees Terms Expiring 2012 Annual Meeting Nominees Terms Expiring Annual Meeting Held 2009
Non-clinical Non-small Cell Lung Cancer
Non-statutory Stock Options Nonadmissions Clause
Nondisclosure Agreement Nondisclosure Confidential Information
Nondisparagement Nonstatutory Stock Options
Not Able Find Collaborators Successfully Form Collaborations Further Not Able Recruit Retain Scientists Management Need Compete
Not Obtain Regulatory Approval Sale Manufacture Drug Products Not Receive Further Milestone Royalty License Payments Current
Not Received Current Pending Notice Nasdaq Regarding Delisting Notes Payable
Notice Notice Annual Meeting Stockholders
Notice Co-signer Traduccion Ingles Requiere Por Ley Notices
Novartis Institute Biomedical Research Inc Now Therefore
Now Therefore Consideration 100 Receipt Sufficiency Hereby Acknowledged Number 000-21429
Number Research Development Programs Result Commercialization Product Furthermore Objectives
Offering Only Limited Experience Regulatory Affairs Some Products Based
Operational Goals Operations Interrupted Damage Laboratory Facilities
Option Intended Incentive Stock Extent Permissible 422 Internal Organization Nature Operations
Other Assets Other Elements Compensation Perquisites
Other Events Other Information
Other Matters Others Fully Described
Outplacement Outside Activities
Overall Policy Oversight Relationship Independent Auditor
Overview Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma Trial Paolo Pucci
Paolo Pucci Chief Executive Officer Parachute Payments
Part Part Business Strategy Involves Collaborative Out-licensing Drug Candidates
Part Other Information Partnered Pipeline
Patents Other Proprietary Rights Fail Protect Business Patents Other Proprietary Rights Fail Protect Business Unable
Patents Propriety Rights Patrick Zenner
Payable Payments Withholding Tax
Performance-based Bonuses Persons Eligible Participate Plan
Peter Lawrence Peter Lawrence Executive Vice President Chief Operating Officer
Peter Lawrence President Chief Operating Officer Pfizer
Pfizer Inc Pharmacia
Pharmacovigilence Adverse Event Reports Phase
Phase Clinical Program Phase Combination Therapy Results Arq 501 Docetaxel
Phase Combination Therapy Results Arq 501 Gemcitabine Phase Dosing Tissue Biopsy Study Royal Marsden Hospital
Phase Interim Data Arq 171 Phase Interim Data Arq 197
Phase Monotherapy Results Arq 501 Phase Program
Phase Results Phase Study
Phase Study Combination Gemcitabine Phase Study Combination Taxotere
Phase Study Monotherapy Pipeline
Please Sign Date Return Thls Proxy Card Promptly Portfolio Growth
Potential Payments Named Executive Officers Termination Change Control Pre-clinical Pipeline
Preclinical Discovery Programs Preclinical Findings
Preclinical Pipeline Preclinical Research Pipeline
Preferred Stock Prepayments Breakage Charges
President Chief Executive Officer Presidential Way Woburn Massachusetts 01801
Presidential Way Woburn Massachusetts 01801 Address Principal Executive Prices
Principal Accounting Fees Services Principal Financial Officer
Product Candidates Subject Lengthy Uncertain Regulatory Process Not Properties
Property Equipment Proposal 1-election Directors
Proposal 4-approval Amendment Amended Restated 1996 Employee Stock Proposal 4-ratification Selection Independent Registered Public Accountants
Proposal 5-ratification Selection Independent Registered Public Accountants Prospectus Amendment Supplement Registration Statement Shall Been Filed
Provision Income Taxes Proxy Solicited Behalf Board Directors Arqule Inc Annual
Proxy Statement Arqule Inc 2008 Annual Report Form Publicity Non-solicitation
Purchase Accounting In-process Research Development Purchase Sale Stock
Purpose Quantitative Qualitative Disclosures Market Risk
Quarterly Report Pursuant Securities Exchange Act 1934 Read Provisions Agreement Understand Agree Each Such
Reasonably Requested Arqule Regarding Commercialization Licensed Product Request Recent Accounting Pronouncements
Recently Issued Accounting Standards Reclassifications
Reconciliation Shared Development Costs References
Registered Securities Act 1933 Registrants Business Operations
Regulation Regulatory Clinical Plans Arq 501
Regulatory Filings Adverse Event Reporting Reimbursable Costs
Related Parties Release
Rely Parties Conduct Most Clinical Trials Failure Perform Remainder Page Intentionally Left Blank
Report Report Audit Committee
Report Executive Compensation Report Independent Registered Public Accounting Firm
Reporting Accounting Changes Interim Financial Statem Reports Information Updates
Representations Representations Warranties
Representations Warranties Covenants Loan Parties Research
Research Development Research Development Alliance
Research Development Costs Research Development Costs Nine-month Periods 2007 12529000 39310000
Research Development Revenue Research Development Revenue Recognition
Research Development Revenues 2006 2005 Periods Related Primarily Research Stage Hit Lead Activities
Research Stage Lead Optimization Research Stages Advancement Criteria
Responsibility Development Licensed Products Restructuring
Restructuring Actions Restructuring Charge
Restructuring Charges Restructuring Charges Credits
Results Operations Retirement Plans
Return Property Revenue
Revenue Recognition Compound Development Revenue Recognition Financial Statements
Revenue Recognition Research Development Revenue Recognition-compound Development
Revenue Recognition-research Development Review Approval Related Person Transactions
Review Regulatory Filings Meetings Rights Not Transferable
Risk Factors Risks Related Collaborations
Risks Related Financial Condition Risks Related Relationships Party Vendors
Roche Research Development Alliance Role Compensation Committee
Role Compensation Nominating Governance Committee Ronald Lindsay Phd
Rst 2007 Compared 2006 Rst 2008 Compared 2007
Safety Sale Leaseback Accounting
Sankyo Schedule
Schedule Ubs Bank Usa Credit Line Agreement Science Committee
Scientific Platforms Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Exchange Washington 20549 Form 10-q
Security Breaches Disrupt Operations Adversely Affect Operating Results Security Breaches Disrupt Operations Harm Operating Results
Security Ownership Certain Beneficial Owners Management Related Stockholder See
Segment Data Selected Drug Development Pipeline
Selected Quarterly Financial Data Separation Agreement General Release
Separation Employment Severability
Severance Payment Shall Furnish Time Purchase Applicable Additional Opinion Each
Share-based Compensation Shares Subject Plan
Show Safety Efficacy Product Candidates Through Expensive Time Signatures
Solvay Some Existing Stockholders Exert Control Over Interests Conflict
Specifications Standards Independence
Stephen Hill Stephen Hill Bch Frcs
Stephen Hill Bch Frcs President Chief Executive Officer Stock Offering
Stock Options Stock Options Payments
Stock Performance Graph Stock Price Extremely Volatile
Stock Purchase Agreement 19th 2008 Between Arqule Inc Stock-based Awards
Stock-based Compensation Stockholder Approval
Stockholder Nominations Stockholder Proposals
Studies Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Substantial Number Shares Outstanding Common Stock Sold Offering Success Depend Partly Ability Operate Without Infringing Misappropriating
Success Depends Efforts Collaborators Not Cannot Control Successors Assigns
Summary Significant Accounting Policies Supplemental Disclosure Cash Flow Information
Supply Licensed Products Development Commercialization Table Contents
Take Advantage Available Accelerated Regulatory Approval Strategies Appropriate Target List
Tax Consequences Tax Consequences Participants
Tax Rules Affecting Nonqualified Deferred Compensation Plans Term Rights
Term Termination Termination Agreement Terminated Pursuant 922 923
Termination Employment Termination Material Definitive Agreement
Terms Advances Territory Unless Prohibited Applicable Laws Provided However Commercially
Thomas Chan Phd Chief Scientific Officer Time Consider Agreement
Time Consider General Release Timothy Barabe
Title Duties Top Form
Tuan Ha-ngoc Underwriters Promptly Such Amendments Supplements Prospectus Necessary Reflect
Unemployment Unregistered Sales Equity Securities Proceeds
Vacation Pay Vice President Chief Scientific Officer Head Arqule Biomedical
Vice President Finance Chief Financial Officer Vote Directors
Vote Internet Wwwproxyvotecom Vote Mail
Vote Phone 1-800-690-6903 Vote Proposals
Vote Required Waivers Further Agreements
Werner Cautreels Werner Cautreels Phd
Whereas Whereas Desires Continue Employ Retain Executive Senior Capacity
Whereas Purchaser Agreed Postpone Receipt Bonus Purchase Shares William Messenger
Witness Whereof Witness Whereof Parties Executed Caused Agreement Execution Date
Witness Whereof Parties Executed Caused Amendment Date Set Woburn 2006
Woburn 2007 Woburn 2008
Woburn 2008 Tokyo Japan Woburn 2009
Woburn Mass 2006 Woburn Mass 2007
Woburn Mass 2008 Woburn Mass 2009
Wyeth Wyeth Pharmaceuticals
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki